Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis - Trial NCT06399835
Access comprehensive clinical trial information for NCT06399835 through Pure Global AI's free database. This Phase 4 trial is sponsored by Seoul National University Bundang Hospital and is currently Recruiting. The study focuses on Type 2 Diabetes. Target enrollment is 120 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Seoul National University Bundang Hospital
Timeline & Enrollment
Phase 4
Feb 01, 2024
Dec 01, 2026
Primary Outcome
Changes of HbA1c from the baseline
Summary
The current study aimed to thoroughly compare a thiazolidinedione and an sodium-glucose
 cotransporter-2 (SGLT2) inhibitor regarding various clinical issues including
 atherosclerosis. Enavogliflozin is compared to Pioglitazone in the glucose-lowering effects
 of adding to the treatment of patients with type 2 diabetes whose HbA1c levels are not
 controlled by Metformin with or without DPP-4 inhibitors. Additionally, the study will
 compare changes in other metabolic or cardiovascular risk factors, such as triglycerides,
 high density lipoprotein cholesterol (HDLc), uric acid, blood pressure, and inflammatory
 markers, between the two drugs.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06399835
Non-Device Trial